Actually, SU11274, a c-MET inhibitor, increased the sensitivity of rhIL-17A-treated PC9 cells to afatinib, suggesting that IL-17A may activate compensatory EGFR signaling via phosphorylating c-Met under afatinib treatment in EGFR-mutant NSCLC cells. Here, MET is linked to non-small cell lung carcinoma.